Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis

Fig. 1

Neoantigen identification and delivery via oncolytic adenovirus vectors. a Schematic representation of neoantigen identification combining WES and MS. This figure was created via resources from BioRender (www.biorender.com). b Design of the neoantigen delivery system. The expression cassette of neoantigen cDNA sequences corresponding to the 29-mer long peptides covering the mutated epitopes was inserted into the E3 region of the survivin promoter (SVP)-regulated oncolytic adenovirus vector Ad5SVPF11 to generate a novel OAV, AdSVP-NAg. C57BL/6 mice inoculated with B16F10 melanoma, MC38 colon carcinoma, or Hep53.4 hepatocellular carcinoma cells were treated with PBS, vector (Ad5SVPF11), SLP, vector combined with SLP, or AdSVP-NAg. Tumor growth curves (c) (n = 6 mice per group), representative images (d) of the IFN-γ ELISpot of neoantigen-specific T cells from the spleen in each group and immunofluorescence images (e) of tumor tissues. The data are shown as the means ± SDs (c) and are representative of two independent experiments (c–e). Significance was calculated by two-way ANOVA (c). *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page